Isomer Capital backs Latent Labs in $50M Series A
Co-Investment Strategy
Direct Access to Europe’s Breakout Companies
Our co-investment strategy provides direct exposure to Europe’s most promising early-stage technology companies, sourced through trusted, long-term partnerships with top-tier VC fund managers. By investing alongside our funds, we access breakout opportunities early, with strong insider knowledge, limited competition, and clear alignment.
Isomer’s co-investments combine the upside potential of venture capital with enhanced data research and deal-level control, allowing us to concentrate capital into high-performing assets.
Key Beliefs
- Access Through Trust – Our ability to co-invest comes from years of trusted relationships. Our VC partners offer us access early, often in oversubscribed rounds
- Signal-Led Selection – Every co-investment is filtered through multiple layers of diligence with enhanced data insight from our primary fund commitments
- Early-Stage Focus, Growth-Stage Discipline – While we invest early, we apply institutional discipline in evaluating product-market fit, founder quality, and market readiness
- Concentrated and Conviction-Driven – We selectively co-invest in only the most compelling, high-conviction opportunities across our portfolios.
Portfolio Examples
Recent Articles
Isomer Capital backs Latent Labs in $50M Series A to revolutionize AI-powered drug discovery At…
EUVC Podcast: Co-Investing with your GP/LP
Listen on EUVC | Listen on Spotify In this episode, Isomer’s Chris Wade and HCVC’s…